Nab-Paclitaxel in MBC: Defining the best patient profile
Gonzalez-Marín et al Curr Cancer Drug Targets 2016
•
Patients with
hypersensitivity reactions
to standard taxanes (as standard paclitaxel-related
HSRs are nearly always due to the presence of polyethylated castor oil in its formulation)
•
Patients with a
higher risk of complications after neutropenia
(HIV, chronic steroid treatment,
prior hematologic malignancy treated with extended radiotherapy or high-dose chemotherapy,
or bone marrow depletion)
•
Patients with
decompensated diabetes
(as corticosteroids are not needed with the
administration of the novel formulation)
Generic Taxanes?
